TW202220984A - Ｏ—醣蛋白—２—乙醯胺基—２—去氧—３—ｄ—哌喃葡糖苷酶抑制劑之結晶形式 - Google Patents

Ｏ—醣蛋白—２—乙醯胺基—２—去氧—３—ｄ—哌喃葡糖苷酶抑制劑之結晶形式 Download PDF

Info

Publication number
TW202220984A
TW202220984A TW110128540A TW110128540A TW202220984A TW 202220984 A TW202220984 A TW 202220984A TW 110128540 A TW110128540 A TW 110128540A TW 110128540 A TW110128540 A TW 110128540A TW 202220984 A TW202220984 A TW 202220984A
Authority
TW
Taiwan
Prior art keywords
crystalline
compound
anhydrous
powder diffraction
ray powder
Prior art date
Application number
TW110128540A
Other languages
English (en)
Chinese (zh)
Inventor
阿斯梅隆 威爾第牙博
泰 金 科雷亞
艾莉兒 黛安 傑金斯
林毅清
李朝敏
Original Assignee
美商百健Ｍａ公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商百健Ｍａ公司 filed Critical 美商百健Ｍａ公司
Publication of TW202220984A publication Critical patent/TW202220984A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
TW110128540A 2020-08-03 2021-08-03 Ｏ—醣蛋白—２—乙醯胺基—２—去氧—３—ｄ—哌喃葡糖苷酶抑制劑之結晶形式 TW202220984A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063060281P 2020-08-03 2020-08-03
US63/060,281 2020-08-03

Publications (1)

Publication Number Publication Date
TW202220984A true TW202220984A (zh) 2022-06-01

Family

ID=77640732

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110128540A TW202220984A (zh) 2020-08-03 2021-08-03 Ｏ—醣蛋白—２—乙醯胺基—２—去氧—３—ｄ—哌喃葡糖苷酶抑制劑之結晶形式

Country Status (18)

Country Link
US (1) US20230286972A1 (https=)
EP (1) EP4188925A1 (https=)
JP (1) JP7789056B2 (https=)
KR (1) KR20230061395A (https=)
CN (1) CN116917284A (https=)
AR (1) AR123132A1 (https=)
AU (1) AU2021322186A1 (https=)
BR (1) BR112023002013A2 (https=)
CA (1) CA3188250A1 (https=)
CL (1) CL2023000327A1 (https=)
CO (1) CO2023002543A2 (https=)
CR (1) CR20230118A (https=)
IL (1) IL300365A (https=)
MX (1) MX2023001469A (https=)
PE (1) PE20231168A1 (https=)
TW (1) TW202220984A (https=)
UY (1) UY39366A (https=)
WO (1) WO2022031701A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2602139B (en) * 2020-12-18 2024-07-24 Nexeon Ltd Electroactive materials for metal-ion batteries
WO2025184490A1 (en) 2024-03-01 2025-09-04 Biogen Ma Inc. N-[4-fluor-5-[[(2s, 4 r)-4-[(6-methoxy-4-pyrimidinyl)oxy]- 2-methyl-1-pyrrolidinyl] methyl ]-2-thiazolyl]acetamid for use in the treatment of alzheimer disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2780014A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013078320A1 (en) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
JP5989805B2 (ja) 2012-02-10 2016-09-07 コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． メチル基変更酵素の調節物質、組成物及びその使用
MA38341B1 (fr) 2013-02-11 2018-11-30 Constellation Pharmaceuticals Inc Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
EP3555087A1 (en) 2016-12-16 2019-10-23 Janssen Pharmaceutica NV Monocyclic oga inhibitor compounds
TWI654978B (zh) 2017-01-27 2019-04-01 美商美國禮來大藥廠 5－甲基－1,2,4－二唑－3－基化合物
WO2018154133A1 (en) 2017-02-27 2018-08-30 Janssen Pharmaceutica Nv [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors
US12180205B2 (en) * 2018-09-19 2024-12-31 Biogen Ma Inc. O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors

Also Published As

Publication number Publication date
CN116917284A (zh) 2023-10-20
PE20231168A1 (es) 2023-07-26
US20230286972A1 (en) 2023-09-14
AU2021322186A1 (en) 2023-04-06
BR112023002013A2 (pt) 2023-05-02
MX2023001469A (es) 2023-06-16
EP4188925A1 (en) 2023-06-07
CR20230118A (es) 2023-06-02
CA3188250A1 (en) 2022-02-10
CO2023002543A2 (es) 2023-06-09
JP7789056B2 (ja) 2025-12-19
UY39366A (es) 2022-02-25
CL2023000327A1 (es) 2023-10-06
JP2023536911A (ja) 2023-08-30
IL300365A (en) 2023-04-01
WO2022031701A1 (en) 2022-02-10
AR123132A1 (es) 2022-11-02
KR20230061395A (ko) 2023-05-08
WO2022031701A9 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
KR102275338B1 (ko) Oga 억제제로서의 n-[4-플루오로-5-[[(2s,4s)-2-메틸-4-[(5-메틸-1,2,4-옥사디아졸-3-일)메톡시]-1-피페리딜]메틸]티아졸-2-일]아세트아미드
US10377750B2 (en) 5-methyl-1,3,4-oxadiazol-2-yl compounds
TW201618786A (zh) 組合療法
US20090048448A1 (en) Salts of cynnamide compound or solvates thereof
CN113840821A (zh) Btk抑制剂的晶型
CA3158079A1 (en) Heterocyclic trpml1 agonists
JP5635181B2 (ja) ニトロイミダゾール系化合物、その製造方法および用途
TW202220984A (zh) Ｏ—醣蛋白—２—乙醯胺基—２—去氧—３—ｄ—哌喃葡糖苷酶抑制劑之結晶形式
TWI619719B (zh) 選擇性ｂａｃｅ１抑制劑
US20200048237A1 (en) A Free Base Oxazine Derivative in Crystalline Form
EA049044B1 (ru) Кристаллические формы ингибитора о-гликопротеин-2-ацетамидо-2-дезокси-3-d-глюкопиранозидазы
US10604541B2 (en) Glucokinase activators and methods of using same
US11999726B2 (en) 5-methyl-4-fluoro-thiazol-2-yl compounds
HK40111611B (zh) 含氮并环类衍生物抑制剂的酸式盐或晶型及其制备方法和应用
HK40111611A (zh) 含氮并环类衍生物抑制剂的酸式盐或晶型及其制备方法和应用
WO2025137366A2 (en) Solid-state forms of stat3 inhibitors and methods of use thereof
NZ754849B2 (en) N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor
HK40009770B (en) N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor
HK40009770A (en) N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor